About Us

Akiram Therapeutics is a Swedish clinical-stage biotechnology company developing innovative targeted radiation therapy for cancer. The therapy is based on a proprietary antibody targeting the cancer marker CD44v6, linked to a radiation component. The drug candidate has demonstrated promising preclinical results in cancer types where effective treatments are currently lacking, and the company sees potential to achieve first-in-class status and orphan drug designation. Akiram is dedicated to advancing research in molecular radiotherapy, with a focus on head and neck cancer, lung cancer, and aggressive thyroid cancer. Headquartered in Uppsala, Sweden, the team comprises experts in radiation research, precision oncology, and drug development.

Subscribe